PT  - JOURNAL ARTICLE
AU  - Sarah J. Fletcher
AU  - Vera P. Pisareva
AU  - Abdullah Khan
AU  - Andrew Tcherepanov
AU  - Neil V. Morgan
AU  - Andrey V. Pisarev
TI  - Role of the novel endoribonuclease SLFN14 and its disease causing mutations in ribosomal degradation
AID  - 10.1101/267633
DP  - 2018 Jan 01
TA  - bioRxiv
PG  - 267633
4099  - http://biorxiv.org/content/early/2018/02/18/267633.short
4100  - http://biorxiv.org/content/early/2018/02/18/267633.full
AB  - Platelets are anucleate and mostly ribosome-free cells within the bloodstream, derived from megakaryocytes within bone marrow and crucial for cessation of bleeding at sites of injury. Inherited thrombocytopenias are a group of disorders characterized by alow platelet count and are frequently associated with excessive bleeding. SLFN14 is one of the most recently discovered genes linked to inherited thrombocytopenia where several heterozygous missense mutations in SLFN14 were identified to cause defective megakaryocyte maturation and platelet dysfunction. Yet, SLFN14 was recently described as a ribosome-associated protein resulting in rRNA and ribosome-bound mRNA degradation in rabbit reticulocytes. To unveil the cellular function of SLFN14 and the link between SLFN14 and thrombocytopenia, we examined SLFN14 (WT/mutants) in in vitro models. Here, we show that all SLFN14 variants co-localize with ribosomes and mediate rRNA endonucleolytic degradation and ribosome clearance. Compare dto SLFN14 WT, expression of mutants is dramatically reduced as a result of post-translational degradation due to partial misfolding of the protein. Moreover, all SLFN14 variants tend to form oligomers. These findings could explain the dominant negative effect of heterozygous mutation on SLFN14 expression in patients’ platelets. Overall we suggest that SLFN14 could be involved in ribosome degradation during platelet formation and maturation.